TH103 / Kalaris Therapeutics - LARVOL DELTA

Kalaris Announces Closing of Merger with AlloVir (GlobeNewswire) - "Kalaris Therapeutics... announced the completion of its previously announced merger with AlloVir....The combined company will operate under the name Kalaris Therapeutics, Inc. and its shares are expected to begin trading on The Nasdaq Global Market on March 19, 2025 under the ticker symbol 'KLRS'. Kalaris is currently developing TH103, a novel, differentiated anti-vascular endothelial growth factor ('VEGF') agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina. TH103 was specifically engineered to address the limitations of current neovascular Age-related Macular Degeneration ('nAMD') therapies and has demonstrated both potent anti-VEGF activity and sustained ocular residence time in preclinical studies. Kalaris expects to report initial data from Part 1 of its ongoing Phase 1 clinical trial of TH103 in the second half of 2025."

M&A • P1 data • Wet Age-related Macular Degeneration